Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects
- PMID: 11471862
- DOI: 10.1177/147323000102900312
Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects
Abstract
Two phase III studies with tamsulosin, a selective alpha1A-adrenergic receptor antagonist, were conducted to evaluate the safety and efficacy of the standard treatment doses of 0.4 mg/day and 0.8 mg/day in patients with symptoms of benign prostatic hyperplasia (BPH). These large-scale clinical trials were the first to include extensive testing for possible drug-induced orthostatic hypotension (OH). The frequency of positive orthostatic tests and magnitude of vital sign changes were compared among tamsulosin and placebo-treated groups. The results indicate that tamsulosin up to 0.8 mg/day does not induce higher risk of OH than that of placebo. Data from post-marketing surveillance (PMS) studies of tamsulosin indicate that the incidence of hypotension and syncope is extremely low in community-dwelling elderly men treated for BPH. From the results of the phase III studies, PMS studies and an active-controlled clinical pharmacology study, we conclude that the orthostatic test is a useful and convenient method to evaluate the risk of OH and syncope during the investigational stage.
Similar articles
-
Tamsulosin for the treatment of benign prostatic hypertrophy.Ann Pharmacother. 2000 Feb;34(2):188-99. doi: 10.1345/aph.18263. Ann Pharmacother. 2000. PMID: 10676828 Review.
-
Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect.Clin Ther. 1997 Jul-Aug;19(4):730-42. doi: 10.1016/s0149-2918(97)80097-5. Clin Ther. 1997. PMID: 9377617 Clinical Trial.
-
Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.Clin Ther. 2009 Nov;31(11):2489-502. doi: 10.1016/j.clinthera.2009.11.024. Clin Ther. 2009. PMID: 20109995 Review.
-
Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.Urology. 1998 Jun;51(6):892-900. doi: 10.1016/s0090-4295(98)00126-5. Urology. 1998. PMID: 9609623 Clinical Trial.
-
A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group.J Urol. 1998 Nov;160(5):1701-6. J Urol. 1998. PMID: 9783935 Clinical Trial.
Cited by
-
Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.Drugs Aging. 2002;19(2):135-61. doi: 10.2165/00002512-200219020-00004. Drugs Aging. 2002. PMID: 11950378 Review.
-
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection.Elife. 2021 Jun 11;10:e61700. doi: 10.7554/eLife.61700. Elife. 2021. PMID: 34114951 Free PMC article.
-
Tamsulosin: an update of its role in the management of lower urinary tract symptoms.Drugs. 2002;62(1):135-67. doi: 10.2165/00003495-200262010-00006. Drugs. 2002. PMID: 11790159 Review.
-
Risks and side effects in the medical management of benign prostatic hyperplasia.Prostate Int. 2024 Jun;12(2):57-64. doi: 10.1016/j.prnil.2023.11.004. Epub 2023 Dec 2. Prostate Int. 2024. PMID: 39036761 Free PMC article. Review.
-
Orthostatic Hypotension in Benign Prostatic Hyperplasia Patients and Its Association With Alpha-1 Antagonist Use: A Comprehensive Literature Review.Cureus. 2023 Aug 25;15(8):e44097. doi: 10.7759/cureus.44097. eCollection 2023 Aug. Cureus. 2023. PMID: 37750139 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical